Shenzhen-listed Chinese pharmaceutical company Haisco Pharmaceutical Group has led a US$15 million series D round of financing in Israeli drug developer Regentis Biomaterials Ltd., says a company announcement. Existing investors including Medica Partners, SCP Vitalife Partners, Generali Financial Holdings, the Technion Research & Development Foundation and the Technion Innovation Opportunities Fund also participated in the […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.